Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Inclusion Criteria:

• Male or female patients, 18 to 65 years of age at screening.
• Palmoplantar Pustulosis
• Further inclusion criteria apply

Exclusion Criteria:

• Presence or known history of anti- Tumor necrosis factor (TNF)-induced Palmoplantar Pustulosis (PPP)-like disease.
• Active or latent tuberculosis
• Further exclusion criteria apply